| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 25 | 2026 | 712 | 3.750 |
Why?
|
| Rotavirus Vaccines | 15 | 2026 | 61 | 2.660 |
Why?
|
| Rotavirus Infections | 18 | 2026 | 281 | 2.570 |
Why?
|
| Influenza Vaccines | 13 | 2026 | 507 | 2.530 |
Why?
|
| Hospitalization | 43 | 2026 | 1950 | 2.240 |
Why?
|
| Respiratory Tract Infections | 13 | 2025 | 298 | 2.050 |
Why?
|
| Gastroenteritis | 15 | 2026 | 308 | 1.920 |
Why?
|
| Respiratory Syncytial Virus Infections | 11 | 2026 | 400 | 1.760 |
Why?
|
| Vaccination | 23 | 2026 | 1060 | 1.630 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2026 | 196 | 1.420 |
Why?
|
| Infant | 66 | 2026 | 13352 | 1.200 |
Why?
|
| Rotavirus | 10 | 2024 | 367 | 1.110 |
Why?
|
| Antiviral Agents | 8 | 2026 | 807 | 1.090 |
Why?
|
| Child, Preschool | 56 | 2026 | 15110 | 0.940 |
Why?
|
| Immunization Programs | 5 | 2020 | 68 | 0.920 |
Why?
|
| Enterovirus Infections | 5 | 2025 | 48 | 0.900 |
Why?
|
| Child | 64 | 2026 | 26341 | 0.880 |
Why?
|
| Respiratory Syncytial Virus, Human | 6 | 2025 | 241 | 0.870 |
Why?
|
| United States | 49 | 2026 | 12072 | 0.790 |
Why?
|
| Case-Control Studies | 20 | 2026 | 3359 | 0.730 |
Why?
|
| Emergency Service, Hospital | 10 | 2025 | 1224 | 0.690 |
Why?
|
| Population Surveillance | 6 | 2025 | 396 | 0.670 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 4 | 2026 | 82 | 0.670 |
Why?
|
| Prospective Studies | 22 | 2025 | 6459 | 0.650 |
Why?
|
| Infant, Newborn | 30 | 2026 | 8635 | 0.620 |
Why?
|
| Reassortant Viruses | 3 | 2016 | 28 | 0.600 |
Why?
|
| Vaccination Coverage | 3 | 2026 | 40 | 0.600 |
Why?
|
| Adolescent | 39 | 2026 | 20987 | 0.600 |
Why?
|
| Epidemiological Monitoring | 3 | 2018 | 69 | 0.590 |
Why?
|
| Metapneumovirus | 3 | 2025 | 54 | 0.580 |
Why?
|
| Humans | 95 | 2026 | 131163 | 0.570 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 7 | 2026 | 131 | 0.570 |
Why?
|
| Enterovirus D, Human | 3 | 2025 | 11 | 0.540 |
Why?
|
| Arbovirus Infections | 1 | 2018 | 30 | 0.540 |
Why?
|
| Viruses | 3 | 2024 | 117 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2026 | 570 | 0.520 |
Why?
|
| Seasons | 9 | 2026 | 335 | 0.510 |
Why?
|
| Female | 61 | 2026 | 70963 | 0.510 |
Why?
|
| Fever | 2 | 2024 | 312 | 0.500 |
Why?
|
| Male | 59 | 2026 | 64957 | 0.490 |
Why?
|
| Paramyxoviridae Infections | 3 | 2025 | 49 | 0.480 |
Why?
|
| Reminder Systems | 2 | 2016 | 62 | 0.480 |
Why?
|
| Immunization | 2 | 2021 | 269 | 0.460 |
Why?
|
| Adenoviruses, Human | 2 | 2025 | 96 | 0.440 |
Why?
|
| Adenovirus Infections, Human | 2 | 2025 | 60 | 0.430 |
Why?
|
| Picornaviridae Infections | 2 | 2025 | 49 | 0.420 |
Why?
|
| Immunization Schedule | 6 | 2026 | 111 | 0.410 |
Why?
|
| Acute Disease | 8 | 2025 | 1153 | 0.410 |
Why?
|
| Texas | 13 | 2026 | 3686 | 0.400 |
Why?
|
| Enterovirus | 2 | 2024 | 48 | 0.380 |
Why?
|
| Hospitals, Pediatric | 7 | 2024 | 808 | 0.370 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 1176 | 0.350 |
Why?
|
| Information Systems | 1 | 2010 | 28 | 0.320 |
Why?
|
| Rhinovirus | 3 | 2025 | 67 | 0.310 |
Why?
|
| Genotype | 8 | 2025 | 2595 | 0.310 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2026 | 514 | 0.310 |
Why?
|
| Autism Spectrum Disorder | 3 | 2021 | 450 | 0.300 |
Why?
|
| Pandemics | 7 | 2026 | 1118 | 0.290 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2023 | 208 | 0.280 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 325 | 0.280 |
Why?
|
| Disease Outbreaks | 2 | 2021 | 311 | 0.280 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 712 | 0.280 |
Why?
|
| Vaccines, Attenuated | 8 | 2022 | 174 | 0.280 |
Why?
|
| Hepatitis B Vaccines | 2 | 2026 | 49 | 0.260 |
Why?
|
| Vaccines | 2 | 2023 | 388 | 0.250 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 3061 | 0.240 |
Why?
|
| Feces | 8 | 2025 | 721 | 0.240 |
Why?
|
| Pediatrics | 1 | 2016 | 1252 | 0.240 |
Why?
|
| Mothers | 3 | 2024 | 388 | 0.240 |
Why?
|
| Croup | 1 | 2025 | 14 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 555 | 0.220 |
Why?
|
| Bronchiolitis | 1 | 2025 | 126 | 0.210 |
Why?
|
| Hepatitis B | 1 | 2026 | 171 | 0.210 |
Why?
|
| Pregnancy | 7 | 2026 | 7512 | 0.210 |
Why?
|
| Professionalism | 1 | 2024 | 46 | 0.200 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2024 | 16 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2025 | 237 | 0.200 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2026 | 262 | 0.200 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 95 | 0.190 |
Why?
|
| Influenza B virus | 4 | 2025 | 102 | 0.190 |
Why?
|
| Guideline Adherence | 1 | 2026 | 387 | 0.190 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 156 | 0.190 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 32 | 0.190 |
Why?
|
| Parents | 5 | 2021 | 1128 | 0.190 |
Why?
|
| Caliciviridae Infections | 1 | 2025 | 286 | 0.180 |
Why?
|
| Prenatal Care | 1 | 2025 | 345 | 0.180 |
Why?
|
| Norovirus | 1 | 2025 | 287 | 0.180 |
Why?
|
| Pneumonia | 1 | 2025 | 341 | 0.180 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2022 | 36 | 0.180 |
Why?
|
| Turbinates | 1 | 2021 | 12 | 0.180 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.180 |
Why?
|
| RNA, Viral | 2 | 2021 | 497 | 0.170 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3829 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 166 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 43 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2026 | 872 | 0.160 |
Why?
|
| Mobile Health Units | 1 | 2020 | 24 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2022 | 285 | 0.150 |
Why?
|
| Outpatients | 1 | 2021 | 262 | 0.150 |
Why?
|
| Family Health | 1 | 2020 | 240 | 0.150 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 124 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2025 | 789 | 0.150 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 16 | 0.150 |
Why?
|
| Antigens, Viral | 3 | 2024 | 395 | 0.140 |
Why?
|
| Communicable Diseases, Imported | 1 | 2018 | 6 | 0.140 |
Why?
|
| Child, Hospitalized | 3 | 2026 | 76 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1559 | 0.140 |
Why?
|
| Family Characteristics | 3 | 2025 | 93 | 0.140 |
Why?
|
| Bites and Stings | 1 | 2018 | 29 | 0.140 |
Why?
|
| Chikungunya Fever | 1 | 2018 | 36 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 919 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 398 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
|
| Travel | 1 | 2018 | 117 | 0.130 |
Why?
|
| Cost of Illness | 3 | 2025 | 297 | 0.130 |
Why?
|
| Dengue | 1 | 2018 | 125 | 0.130 |
Why?
|
| Autistic Disorder | 1 | 2020 | 398 | 0.120 |
Why?
|
| West Nile Fever | 1 | 2018 | 145 | 0.120 |
Why?
|
| Coinfection | 1 | 2018 | 187 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.120 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 25 | 0.120 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 781 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2023 | 844 | 0.110 |
Why?
|
| Genome, Viral | 1 | 2016 | 165 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 139 | 0.110 |
Why?
|
| Database Management Systems | 1 | 2014 | 26 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 242 | 0.100 |
Why?
|
| Phylogeny | 1 | 2016 | 689 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2010 | 27 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2550 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 351 | 0.100 |
Why?
|
| Adult | 5 | 2026 | 31282 | 0.090 |
Why?
|
| Risk Factors | 5 | 2026 | 11074 | 0.090 |
Why?
|
| Patient Acuity | 2 | 2022 | 66 | 0.090 |
Why?
|
| Hospitals | 2 | 2026 | 435 | 0.080 |
Why?
|
| Serum | 1 | 2010 | 41 | 0.080 |
Why?
|
| Hospital Information Systems | 1 | 2010 | 42 | 0.080 |
Why?
|
| Time Factors | 3 | 2025 | 6196 | 0.070 |
Why?
|
| Young Adult | 2 | 2025 | 10103 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2701 | 0.070 |
Why?
|
| Ambulatory Care | 2 | 2026 | 401 | 0.070 |
Why?
|
| Informed Consent | 1 | 2010 | 351 | 0.070 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2026 | 60 | 0.060 |
Why?
|
| Palivizumab | 1 | 2026 | 49 | 0.060 |
Why?
|
| Absenteeism | 1 | 2024 | 20 | 0.050 |
Why?
|
| Vaccination Refusal | 1 | 2024 | 19 | 0.050 |
Why?
|
| Vomiting | 1 | 2025 | 103 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 5063 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2024 | 40 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2023 | 6 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 2085 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2024 | 164 | 0.050 |
Why?
|
| Diarrhea | 1 | 2025 | 301 | 0.050 |
Why?
|
| Crowding | 1 | 2023 | 12 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2026 | 222 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2026 | 501 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2024 | 188 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2022 | 35 | 0.050 |
Why?
|
| Coronavirus | 1 | 2022 | 27 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 787 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2021 | 19 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2024 | 406 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.040 |
Why?
|
| Life Support Care | 1 | 2022 | 51 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 118 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 407 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 260 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2022 | 579 | 0.040 |
Why?
|
| Length of Stay | 1 | 2026 | 1421 | 0.040 |
Why?
|
| Transients and Migrants | 1 | 2020 | 30 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 141 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 548 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 2825 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 79 | 0.030 |
Why?
|
| Urban Population | 2 | 2010 | 287 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1205 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2020 | 466 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1445 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2022 | 526 | 0.030 |
Why?
|
| Critical Illness | 1 | 2022 | 630 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 981 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 462 | 0.030 |
Why?
|
| Asthma | 1 | 2025 | 922 | 0.030 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 13 | 0.030 |
Why?
|
| Chickenpox Vaccine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 2016 | 33 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1595 | 0.030 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 35 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3711 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 501 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 327 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 125 | 0.030 |
Why?
|
| Software Design | 1 | 2014 | 21 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 562 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2014 | 43 | 0.030 |
Why?
|
| Premature Birth | 1 | 2019 | 428 | 0.030 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2014 | 138 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 179 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5196 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 352 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3464 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 889 | 0.020 |
Why?
|
| Presumed Consent | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hospitals, Maternity | 1 | 2010 | 8 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 235 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 151 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 422 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2026 | 17753 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 21025 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 2304 | 0.010 |
Why?
|
| Middle Aged | 1 | 2025 | 28601 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3436 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1634 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 6099 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 12936 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 33912 | 0.010 |
Why?
|